Date: 2014-09-04
Type of information: Capital increase
Company: Biomay (Austria)
Investors: existing shareholders
Amount: €2.8 million
Funding type: capital increase
Planned used: The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development.
Others: * On September 4, 2014, Biomay announced that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million.
Therapeutic area: Allergic diseases
